Galapagos NV (BVMF:G1LP34)

Brazil flag Brazil · Delayed Price · Currency is BRL
8.85
+0.19 (2.19%)
At close: Feb 10, 2026
Market Cap11.46B +27.9%
Revenue (ttm)1.79B +10.3%
Net Income-2.73B
EPS-41.38
Shares Outn/a
PE Ration/a
Forward PE13.07
Dividendn/a
Ex-Dividend Daten/a
Volume3
Average Volume14
Open8.79
Previous Close8.66
Day's Range8.79 - 8.85
52-Week Range6.48 - 10.00
Beta0.10
RSI48.59
Earnings DateFeb 23, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 558
Stock Exchange Brazil Stock Exchange
Ticker Symbol G1LP34
Full Company Profile

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial numbers in EUR Financial Statements